PropertyValue
?:effect
?:hasPrimarySource
?:impact
  • increase
?:interaction
  • The risk or severity of adverse effects can be increased when Erenumab is combined with Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated).
  • The risk or severity of adverse effects can be increased when Erenumab is combined with Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated).
?:objectDrug
?:object_hasDrugBankID
?:precipitantDrug
?:precipitant_hasDrugBankID
is ?:subClassOf of
?:type

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/C4542165_interactsWith_C3888362>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/C4542165_interactsWith_C3888362>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all